Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 3 of 812345...Last »

Doctors devise care plan for babies as Zika threat looms in U.S.

As U.S. public health officials try to determine whether Zika has arrived in the country, doctors are establishing guidelines on how to care for the rising number of babies whose mothers were infected with the virus during pregnancy.

Read More »

Gilead’s Odefsey Meets Primary 48-Week Objective in Two Phase 3b Studies

Gilead Sciences Inc. announced that two Phase 3b switch studies evaluating Odefsey (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) for the treatment of HIV-1 infection met their primary objectives.

Read More »

Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab

Merck said the U.S. Food and Drug Administration has requested the submission of new data and analyses from the MODIFY I and MODIFY II clinical trials previously submitted to the pending Biologics Licensing Application for bezlotoxumab, an investigational agent for prevention of Clostridium difficile (C. difficile) infection recurrence.

Read More »

Medical Advertising Hall of Fame: View from the Top 2016

Healthcare agencies were brought together for the Medical Advertising Hall of Fame’s “View from the Top” leadership forum.

Read More »

Roche CEO fears hit to UK drug research from Brexit vote

Britain’s decision to leave the European Union threatens to undermine its position as a center for drug research and UK patients could fall behind others in Europe in getting access to new drugs, Roche’s chief executive said.

Read More »

Amgen, Allergan biosimilar found as effective as Roche cancer drug

Amgen Inc. and Allergan Plc said their copycat version of Roche Holding AG’s blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study.

Read More »

Biogen profit easily beats Street view; CEO to leave

Biogen reported Q2 profit that blew past Wall Street estimates; Chief Executive George Scangos will step down in the coming months once a successor is found.

Read More »

Theranos hires executives in regulatory, compliance push

Blood-testing company Theranos Inc. said it hired two executives to oversee regulatory, quality and compliance standards, as the company tries to recover from a series of regulatory sanctions and investigations.

Read More »

Struggling Aegerion Axes 13% of Workforce, Withdraws Cholesterol Drug from the EU

Aegerion Pharmaceuticals continues to struggle as it moves to merge with QLT Inc. Aegerion has announced that not only will it withdraw its high cholesterol drug lomitapide from the European Union and other global markets, the company will also slash another 13 percent of its workforce.

Read More »

Roche beats forecasts on new drugs, one-off gain

Roche beat market expectations for adjusted net income in the first-half 2016, helped by cancer drug sales but also inflated by a one-off gain from its pensions scheme.

Read More »

Galenica to buy biotech firm Relypsa for $1.5 billion, ahead of split

Galenica has agreed to buy Relypsa for $1.53 billion, paying a big premium for the Californian biotech company to strengthen its Vifor Pharma unit ahead of splitting up the Swiss healthcare group.

Read More »

Actelion hikes core profit guidance after strong first half

Swiss biotechnology firm Actelion raised its guidance for a second time, buoyed by strong uptake of its new pulmonary arterial hypertension (PAH) medicines.

Read More »

Amgen Announces Settlement Of Securities Litigation

Amgen announced that it has entered into an agreement with plaintiffs to resolve In re Amgen Inc. Securities Litigation, CV-07-2536 PSG, a previously disclosed securities class action lawsuit pending in the United States District Court for the Central District of California.

Read More »

Razorfish Health Announces the Promotions of Three Account Leaders

Promotions demonstrate agency commitment to strategic thinking and client-focused delivery excellence   July 20, 2016, PHILADELPHIA, Penn. — Razorfish Health, a uniquely integrated health marketing agency, announces the promotion of three individuals on the Account Management team.  Lisa Turzio has been promoted to SVP, Group Account Director, Sarah Bast to VP, Group Account Director and […]

Read More »

Only extreme sitting linked to increased heart disease risk

Being sedentary, at least in moderation, is unlikely to cause heart disease, according to a new review of past research.

Read More »

Abbott quarterly sales and profit exceed forecast

Abbott Laboratories reported better-than-expected quarterly sales and profit with strong sales in its medical device business.

Read More »

Mylan gets EU approval for Meda purchase, subject to conditions

EU antitrust regulators said they had cleared generic drugmaker Mylan’s planned cash-and-stock purchase of Sweden’s Meda subject to it selling certain assets.

Read More »

Your inhaler’s watching you: drugmakers race for smart devices

Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly.

Read More »

Merck & Co. to Set Up Shop in South San Francisco

Drugmaking giant Merck is setting up a new West Coast headquarters in the Bay Area.

Read More »

Zafgen Pinks Slips 34% of Workforce, Scraps Lead Obesity Drug After Deaths

After a lengthy clinical hold by the U.S. Food and Drug Administration, Boston-based Zafgen has decided to halt development of obesity drug beloranib, shift its focus to another obesity drug (ZGN-1061) and lay off 34 percent of its staff. In addition, two executives are leaving the company.

Read More »

Page 3 of 812345...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2018 Focus: Biotech, Payer Access, DTC and more!

Subscribe

Ad Right Bottom

Main Navigation